Phase 3 randomized double-blind trial of HRS9531 Injection for weight loss in overweight or obese adults

Phase 3, randomised, double-blind trial of HRS9531 in obesity and Overweight (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Percent change in body weight from baseline at 48 weeks and Proportion of subjects achieving ≥5% weight loss from baseline at 48 weeks. Started May 2024; status: completed.